Background : Pulse wave velocity (PWV) is a well-known index of arterial atherosclerosis and an important risk factor for cardiovascular and all cause death. Because PWV is susceptible to changes in blood pressure, it is difficult to identify whether the improvement of PWV is achieved by the blood pressure lowering effect, or by some other effect beyond it. In this study, we investigated the effect of telmisartan on PWV under the equivalent blood pressure with the control. Methods : A total of 49 diabetic outpatients with hypertension were assigned to telmisartan group (n=27) and control group (n=22) and observed for 12 months. In the telmisartan group, telmisartan (20 or 40 mg/day) was administered instead of, or in addition to, a pretreatment anti-hypertensive drug, and in the control group, pretreatment anti-hypertensive drugs were continued. Results : In both the telmisartan group and the control group, blood pressure did not change significantly during the observation period. Glycemic controls and ankle pressure index (API) did not change significantly in either group. In the telmisartan group, PWV was improved significantly, while in the control group the PWV showed an increase. AER was also improved significantly in the telmisartan group, but it increased in the control group significantly. We observed no adverse events in either group during the observation period. Conclusion : Telmisartan improved PWV and AER, but in the control group, both PWV and AER increased under the equivalent blood pressure control. These findings suggest that telmisartan has favorable effects on arterial and renal functions beyond blood pressure lowering.
|Number of pages||7|
|Publication status||Published - Dec 1 2007|
All Science Journal Classification (ASJC) codes